Randomised clinical trials are the gold standard for evaluating
new treatments and moreover, they have become part of
everyday practice. Many international guidelines recommend
RCT at certain stages of oncology diseases. For example, the
NCCN guideline for Non-Hodgkin’s lymphoma treatment
suggests RCTs for relapsed patients who are non-candidates
for stem cell transplant. Therefore, it is important that RCTs
provide accurate information that can be extrapolated to all
the target population. The article is written by Maxim Kosov,
MD (USA), Maxim Belotserkovskiy, MD (Germany) and John
Riefler, MD (USA), from PSI CRO AG (Zug, Switzerland).
https://www.jforcs.com/7/wp-content/uploads/2016/02/9-J102-2.pdf